Navigation Links
Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study
Date:7/21/2008

LONDON, July 21 /PRNewswire/ -- The SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) study has investigated the effects of intensive cholesterol lowering with the combination of simvastatin (40 mg daily) and ezetimibe (10 mg daily) in patients with aortic stenosis.

Aortic stenosis (which involves partial blockage of the aortic valve in the heart) is a relatively common disease among older people in Western populations. Left untreated, it can progress to death from heart failure or cardiac arrest. Aortic valve replacement for severe symptoms is the second most frequent type of heart surgery. Apart from surgery, there is no medical therapy known to prevent or heal this condition. Population studies and other scientific research indicate that a high blood level of LDL-cholesterol (so called "bad cholesterol) is a risk factor for developing aortic stenosis and may be involved in the pathological process. Treatment to lower LDL-cholesterol in many other types of patient has been shown to produce substantial reductions in the rates of heart attacks, strokes and other adverse outcomes.

The SEAS study is the first large-scale randomised trial to assess the effects of lowering LDL-cholesterol in patients with aortic stenosis. The study was initiated and designed by academic researchers in Scandinavia, and carried out at 173 clinical centres in Norway, Denmark, Sweden, Finland, Germany, UK and Ireland. It included 1873 patients with mild to moderate aortic stenosis without symptoms who were not considered to have a clear indication for treatment with cholesterol-lowering drugs. Patients were randomly assigned to receive either intensive cholesterol lowering with the combination of simvastatin (40 mg daily) and ezetimibe (10 mg daily) or matching placebo. The first patient was included in 2001. The study was completed according to the study plan when the last patient included had been followed for 4 years (March 2008). Vital status at the end of the stu
'/>"/>

SOURCE ;
Copyright©2008 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/25/2008)...vention and Treatment Strategies--, PHILADELPHIA,...e,discovered gene mutations that are the main caus... neuroblastoma. In addition, the researchers found...n high-risk forms of,non-inherited neuroblastoma, ...very enables us to offer the first genetic tests t...
(Date:8/25/2008)...atient calls it a ,miracle, LATHAM, N.Y., Aug. 2...age Guided Radiation Therapy program at Community ...cancer patients using RapidArc(TM),radiotherapy te..., an,advancement that delivers a highly-precise im...) treatment in two minutes or less., RapidArc tre...
(Date:8/25/2008)... CLL Retreatment and Japanese Development Studies ...N, Denmark, August 25 /- Ge...ofatumumab in chronic lymphocytic,leukemia and non...nced today plans to begin four studies of,ofatumum...cular,non-Hodgkin,s lymphoma (NHL) this year., "G...
(Date:8/22/2008)...ust 22 /-, - Dangerous Bacteria Infe...etimes something well-tried can also be innovative... to be very antimicrobial. This,ability is now pla...gerous,hospital germs. In a worldwide noted field ...c in Wandsbek in Hamburg, Germany, was equipped wi...
Breaking Medicine Technology:Gene That Causes Childhood Cancer Neuroblastoma Is Found 2Gene That Causes Childhood Cancer Neuroblastoma Is Found 3Gene That Causes Childhood Cancer Neuroblastoma Is Found 4Image Guided Radiation Therapy in Latham, NY. Now Fighting Cancer Using Fast and Precise RapidArc(TM) Radiotherapy Technology 2Image Guided Radiation Therapy in Latham, NY. Now Fighting Cancer Using Fast and Precise RapidArc(TM) Radiotherapy Technology 3Genmab Announces Upcoming Ofatumumab Studies 2Genmab Announces Upcoming Ofatumumab Studies 3Genmab Announces Upcoming Ofatumumab Studies 4Copper Eliminates Resistant Hospital Germs in a Worldwide Field Test 2Copper Eliminates Resistant Hospital Germs in a Worldwide Field Test 3Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference 714 1Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference 714 2Lexicon Pharmaceuticals to Present at the UBS Global Life Sciences Conference 712 1Lexicon Pharmaceuticals to Present at the UBS Global Life Sciences Conference 712 2Beaumont Patients 1st to get Next Generation of Radiation Treatment 337 1Beaumont Patients 1st to get Next Generation of Radiation Treatment 337 2Repeat steroids to premature infants linked to cerebral palsy 1654 1Repeat steroids to premature infants linked to cerebral palsy 1654 2
...Selective Anti-VEGF Antibodies Inhibited Tumor Gro...Cancer Model -, , - Peregrine,s Antibodies that Se...lly Have Advantages over Non-Selective Approaches ... Fully Human,Antibody Support , Advancing Peregrin...LOS ANGELES and TUSTIN, Calif., April 16, 2007,/PR...
...pril 16, 2007 /PRNewswire/ -- Expression,Genetics,...,clinical study evaluating the Company,s lead drug...University of Alabama at,Birmingham and , evaluate... biological activity of the EGEN-001 in 13 patient...r. The product,utilizing the Company,s proprietar...
Other Medicine Technology:Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 2Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 3Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 4Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 5Expression Genetics, Inc. Announces Successful Completion of Phase,I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer 2Expression Genetics, Inc. Announces Successful Completion of Phase,I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer 3Expression Genetics, Inc. Announces Successful Completion of Phase,I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer 4
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
...A new dryer that is capable of eliminating parasit... from hair with a single half hour treatment is mu...ches claim researchers. The dryer capable of dryi... lower temperature than that of a regular hair dry...
...The Pakistan Medical Association (PMA) plans to mo...ast bowlers Shoaib Akhtar and Mohammed Asif.// "T...tside world and the International Cricket Council ...was not meted out to the two," PMA president Umer ...
...'Sexual Harassment' at the workplace faced by wome...days and many of them are not ready to come out op...lkata, West Bengal, with 135 in-depth interviews o...d two private hospitals over a period of 11 months...
...Russia a country known for its lax regulations reg...rowning themselves in liquor without any person// ... So it comes as little surprise when recent estima...ie annually from disorders which are linked to alc...
Other Medicine News:Health News:Lice now dried to death by novel dryer 2Health News:Doctors, Nurses Face Sexual Harassment At Work Place 2
...mistry system brings versatility in a very compact...nnovation and integration, the Dimension Xpand int... Dimension technology, specifically tailored for t...affordable, easy-to-use system to give you more of...
...chemistry integrated systems combine the ease of u... Multiply and Quicklyte integrated multisensors an...et the challenges of your laboratory. Models of in...t over 97% of your chemistry testing needs on a si...
...new level of speed, intelligence and flexibility. ...er level of throughput, which translates to an eve...nd time. Consider Aeroset's highly advanced softwa...screens with automated testing functions to help y...
Modular Pre-Analytics is an integral component of the new modular systems platform which combines pre-analytics, clinical chemistry and immunochemistry.
Medicine Products: